Systematic Review and Meta‑analysis of Shenfu Injection on Treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease

The objective of the study was to systematically evaluate the efficacy and safety of Shenfu injection in the treatment of patients with acuteexacerbation of chronic obstructive pulmonary disease (AECOPD). A total of 15 randomized controlled trials involving 1198 patients wereincluded. The results of meta?analysis showed that compared with the control group, the experimental group can improve the total clinicaleffective rate in AECOPD patients (relative risk = 1.15, 95% confidence interval [CI] [1.09, 1.21], P < 0.000 01), improve the pulmonaryfunction levels: forced expiratory volume in one second (FEV1) (standardized mean difference = 1.88, 95% CI [0.89, 2.88], P = 0.000 2)and the FEV1/forced vital capacity (FVC) ratio (FEV1/FVC) (mean difference [MD] = 3.96, 95% CI [2.74, 5.19], P < 0.000 01); improvethe arterial blood oxygen partial pressure (MD = 6.03, 95% CI [4.58, 7.48], P < 0.000 01), and reduce the arterial blood partial pressure ofcarbon dioxide (MD = ?4.59, 95% CI [?6.91, ?2.26], P = 0.000 01), and the white blood cell count in pulmonary infection may be improved(MD = ?1.16, 95% CI [?1.63, ?0.68], P < 0.000 01). The study showed that the efficacy of experimental group in the treatment of AECOPDis better than control group. Due to the limitation of the number and quality of included studies, this conclusion needs more high qualitystudies to confirm.

Systematic Review and Meta-analysis of Shenfu Injection on Treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease

The objective of the study was to systematically evaluate the efficacy and safety of Shenfu injection in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). A total of 15 randomized controlled trials involving 1198 patients were included. The results of meta-analysis showed that compared with the control group, the experimental group can improve the total clinical effective rate in AECOPD patients(relative risk = 1.15, 95% confidence interval [CI] [1.09, 1.21], P 0.000 01), improve the pulmonary function levels: forced expiratory volume in one second(FEV1)(standardized mean difference = 1.88, 95% CI [0.89, 2.88], P = 0.000 2) and the FEV1/forced vital capacity(FVC) ratio(FEV1/FVC)(mean difference [MD] = 3.96, 95% CI [2.74, 5.19], P 0.000 01); improve the arterial blood oxygen partial pressure(MD = 6.03, 95% CI [4.58, 7.48], P 0.000 01), and reduce the arterial blood partial pressure of carbon dioxide(MD =-4.59, 95% CI [-6.91,-2.26], P = 0.000 01), and the white blood cell count in pulmonary infection may be improved(MD =-1.16, 95% CI [-1.63,-0.68], P 0.000 01). The study showed that the efficacy of experimental group in the treatment of AECOPD is better than control group. Due to the limitation of the number and quality of included studies, this conclusion needs more high quality studies to confirm.